Search Contact
This page is available in multiple languages
Select Language

Ulisse Biomed S.p.A. lists on AIM Italia

Back

  • Twenty–second listing of 2021 on Borsa Italiana’s AIM Italia
  • Ulisse Biomed S.p.A. brings the total number of companies listed on Borsa Italiana’s AIM Italia to 153
  • Total placement volume of the offering equal to €5 million with listing

Milan – 6 August 2021 – Borsa Italiana, part of the Euronext Group, today congratulates Ulisse Biomed S.p.A. on its listing on Borsa Italiana’s AIM Italia.

Ulisse Biomed S.p.A. is a healthcare biotech company operating in the diagnostics, theranostics and therapeutics.

Ulisse Biomed S.p.A. is the twenty–second company to list since the beginning of the year on Borsa Italiana’s market dedicated to small and medium-sized companies and brings the total number of firms currently listed on AIM Italia to 153.

In the placement phase, Ulisse Biomed S.p.A. raised €4.5 million, excluding the potential exercise of an over-allotment option. In case of the full exercise of the over-allotment option, the total amount raised will be €5 million. The free float at the time of admission was 31,82% and the market capitalisation at IPO was €14.5 million.

Matteo Petti, CEO, Ulisse Biomed S.p.A., said: "The listing today will allow us to finance our growth and bring to the market the products that are on our technological platforms, enhancing, in this way, our visibility, standing and confirming our independent growth. We will continue to focus our efforts in order to make personalised treatments an affordable reality to everyone, using the countless opportunities offered by the use of DNA, for the benefit of our company and our shareholders. We present ourselves to the market with the structure of a public company, hoping to meet expectations with positive results and the trust that has been placed in us."

Ulisse Biomed S.p.A.

Matteo Petti, CEO of Ulisse Biomed S.p.A. rang the bell during the market open ceremony this morning to celebrate the Initial Public Offering of the company.

Ulisse Biomed S.p.A.

Ulisse Biomed S.p.A. is an healthcare biotech company operating in the diagnostics, theranostics and therapeutics with the mission to develop innovative solutions in these fields. The company has three proprietary technology platforms capable of generating innovative and competitive products: Sagitta (molecular diagnostics), NanoHybrid (theranostics and diagnostics) and Aptavir (therapeutics). UBM owns a portfolio of intellectual properties made of 8 international patent applications that cover the three technology platforms (3 related to Sagitta, 2 related to NanoHybrid, 1 related to Aptavir and 2 transversal to the three platforms), two of them are granted in Italy and in Europe.

Download press release - Ulisse Biomed S.p.A.

Press Release Footer

About Euronext 
Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody, to solutions for issuers and investors. Euronext runs MTS, one of Europe’s leading electronic fixed income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway, and Portugal. As of March 2025, Euronext’s regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway, and Portugal host nearly 1,800 listed issuers with around €6.3 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 25% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices. 
For the latest news, follow us on X (x.com/euronext) and LinkedIn (linkedin.com/company/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2025, Euronext N.V. - All rights reserved.